Impact of the clinical frailty scale on clinical outcomes and bleeding events in patients with ST-segment elevation myocardial infarction

Autor: Yasuhiro Uchida, Jun Yonekawa, Takatsugu Hiramatsu, Junji Watanabe, Hideki Ishii, Akinori Satake, Tatsuaki Matsubara, Hitoshi Ichimiya, Daiki Yamashita, Koji Mizutani, Masaaki Kanashiro, Tetsuya Amano, Satoshi Ichimiya, Masanari Kurobe, Yuichiro Makino, Toyoaki Murohara, Yoshiaki Mizutani
Rok vydání: 2021
Předmět:
Male
musculoskeletal diseases
medicine.medical_specialty
Time Factors
medicine.medical_treatment
Population
Postoperative Hemorrhage
030204 cardiovascular system & hematology
03 medical and health sciences
Percutaneous Coronary Intervention
0302 clinical medicine
Japan
Risk Factors
Internal medicine
medicine
Humans
Prospective Studies
Registries
cardiovascular diseases
030212 general & internal medicine
Myocardial infarction
education
Aged
Retrospective Studies
education.field_of_study
Frailty
business.industry
Incidence
Incidence (epidemiology)
Hazard ratio
virus diseases
Percutaneous coronary intervention
Middle Aged
medicine.disease
Confidence interval
nervous system diseases
Conventional PCI
ST Elevation Myocardial Infarction
Female
Cardiology and Cardiovascular Medicine
business
human activities
Mace
Follow-Up Studies
Zdroj: Heart and Vessels. 36:799-808
ISSN: 1615-2573
0910-8327
DOI: 10.1007/s00380-020-01764-0
Popis: The Clinical Frailty Scale (CFS) is a simple tool to assess patients' frailty and may help to predict adverse outcomes in elderly patients. The aim of the present study was to examine the impact of CFS on clinical outcomes and bleeding events after successful percutaneous coronary intervention (PCI) in ST-segment elevation myocardial infarction (STEMI). We enrolled 266 consecutive patients with STEMI who underwent primary PCI in between January 2015 and June 2018. Patients were categorized into two groups based on the CFS stages: CFS 1-3 and CFS ≥ 4. We collected the data and evaluated the relationship between the CFS grade and the incidence of major adverse cardiovascular events (MACE) and Bleeding Academic Research Consortium 3 or 5 bleeding events. Of these patients, CFS ≥ 4 was present in 59 (22.2%). During the follow-up, 37.3% in the CFS ≥ 4 group and 8.2% in the CFS 1-3 group experienced MACE. In Kaplan–Meier analysis, the proportion of MACE-free survival for 4 years was significantly lower in the CFS ≥ 4 group (log-rank P
Databáze: OpenAIRE
Externí odkaz: